[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"valve-disease-heart\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:valve-disease-heart":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,45,77,101,122,159,187,219,249,270,294],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100635406","hummingbird-ice-study-100635406",false,"NCT07552272","Hummingbird ICE Study","Inclusion Criteria:\n\n* 18 years of age\n* Willing to provide written, dated and signed, informed consent\n* Undergoing percutaneous cardiac intervention procedures in with VeriSight Pro is used\n\nExclusion Criteria:\n\n* Contraindicated for ICE catheter placement or considerations that make placement of VeriSight not technically feasible\n* Known contraindicated conditions include sepsis, major coagulation abnormalities, presence of any intracardiac thrombus, presence of class IV angina or heart failure, deep vein thrombosis, or significant peripheral vascular disease","ALL","18 Years",{"count":18,"type":19},1000,"ESTIMATED","2 Days","OBSERVATIONAL","The goals of this observational study are to collect data and ultrasound images using the Philips VeriSight Pro intracardiac echocardiography (ICE) catheter to assess safety and effectiveness and to support development efforts of the VeriSight Pro imaging platform.",[24,25,26,27,28,29],"ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION","Atrial Fibrillation (AF)","Valve Disease, Heart","Atrial Septal Defect","Patent Foramen Ovale","Tricuspid Valve Disease",[31,32],"Intracardiac Echocardiography (ICE)","VeriSight","NOT_YET_RECRUITING","2026-05-18",{"date":36,"type":37},"2026-05-22","ACTUAL",{"date":39,"type":19},"2026-07",{"date":41,"type":19},"2031-07",{"name":43,"class":44},"Philips Clinical & Medical Affairs Global","INDUSTRY",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100622105","soft-foam-dressings-for-pressure-injury-prevention-of-cardiac-surgery-100622105","NCT07379294","Soft Foam Dressings for Pressure Injury Prevention of Cardiac Surgery","Effectiveness of Using Soft Foam Dressings in Preventing Pressure Injuries During Cardiac Surger","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Scheduled to undergo cardiac surgery under general anesthesia\n* Use of cardiopulmonary bypass (CPB) during surgery\n* Expected surgical duration greater than 4 hours\n* Intact skin without pre-existing pressure injury prior to surgery\n\nExclusion Criteria:\n\n* Surgical position other than supine\n* Long-term bedridden status prior to hospital admission\n* Altered consciousness or inability to cooperate\n* History of stroke with residual limb weakness",{"count":53,"type":19},80,"INTERVENTIONAL",[56],"NA","The purpose of this study is to evaluate whether the application of soft foam dressings can reduce the occurrence of surgery-related pressure injuries among patients undergoing cardiac surgery. Specifically, this research aims to investigate differences in pressure injury outcomes before and after the intervention, and to assess the preventive effectiveness of soft foam dressings as an adjunctive skin-protection strategy.",[59,60,26,61,62,63,64,65,66],"CAD - Coronary Artery Disease","CABG","Aortic Diseases","Valve Heart Stenosis","Aortic Aneurysm","Mitral Disease","AORTIC VALVE DISEASES","Aortic Dissection","2026-05-11",{"date":69,"type":37},"2026-05-14",{"date":71,"type":19},"2026-05-31",{"date":73,"type":19},"2027-05-30",{"name":75,"class":76},"Shih,Wen-Chi","OTHER",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100610232","observational-study-of-patients-undergoing-diagnostic-right-heart-catheterization-100610232","NCT07224906","Observational Study of Patients Undergoing Diagnostic Right Heart Catheterization","Observational Study of the HemoCept Device During Right Heart Catheterization at Boulder Heart","Inclusion Criteria:\n\n* Subjects or representatives must have voluntarily signed the informed consent form before any study related procedures.\n* Subjects can be any gender but must be age 18 or older.\n* Subject is able and willing to provide informed consent and HIPAA authorization.\n* Subject is able and willing to meet all study requirements.\n* Scheduled for a diagnostic right heart catheterization (RHC-only or combined RHC+LHC; left-heart-only procedures are not eligible)\n\nExclusion Criteria:\n\n* Subject is pregnant, breastfeeding, or intends to become pregnant during this study.",{"count":85,"type":19},50,"The objective of this observational pilot study is to collect HemoCept device data from subjects undergoing diagnostic right heart catheterization (RHC) procedures.",[88,89,26],"Pulmonary Hypertension","Congestive Heart Failure(CHF)","RECRUITING","2026-04-09",{"date":93,"type":37},"2026-04-13",{"date":95,"type":37},"2025-12-01",{"date":97,"type":19},"2027-01",{"name":99,"class":44},"HemoCept Inc.",1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":108,"targetDuration":110,"studyType":21,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100368139","medtronic-cardiac-surgery-pmcf-registry-100368139","NCT04073420","Medtronic Cardiac Surgery PMCF Registry","Medtronic Cardiac Surgery Post Market Clinical Follow-up Registry","Inclusion Criteria:\n\n1. Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n2. Patient has or is intended to receive or be treated with an eligible product\n3. Patient is within enrollment window of treatment\u002Ftherapy received at the time of their initial Registry enrollment, or meets criteria for retrospective enrollment\n\nExclusion Criteria:\n\n1. Patient who is, or is expected to be, inaccessible for follow-up\n2. Patient prohibited from participation by local law\n3. Patient is currently enrolled in or plans to enroll in any concurrent investigational drug and\u002For device study that may confound results",{"count":109,"type":19},2700,"10 Years","This registry is being conducted to support ongoing post-market surveillance activities.",[26],"2026-04-08",{"date":93,"type":37},{"date":116,"type":37},"2019-12-02",{"date":118,"type":19},"2039-12-31",{"name":120,"class":44},"Medtronic Cardiac Surgery",26,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":54,"phases":132,"briefSummary":134,"conditions":135,"keywords":141,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":100},"100626363","phase-3-apixaban-vs-warfarin-in-af-pts-first-three-months-after-repair-or-bio-avr-mvr-100626363","NCT07434661","Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR","Safety and Efficacy of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in the First Three Months After Mitral or Aortic Biological Valve Replacement or Repair","SAFE-HEART","Inclusion Criteria:\n\n* Age ≥18 years at the time of enrolment\n* Open heart aortic or mitral valve repair or biological valve replacement in the last 10 days\n* Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),\n* Informed consent from either the patient or a substitute decision-maker.\n\nExclusion Criteria:\n\n* Mechanical valve replacement\n* Antiphospholipid syndrome (triple positive)\n* Severe renal failure (Cockcroft-Gault equation; creatinine clearance \\\u003C15 ml\u002Fmin)\n* Known significant liver disease (Child-Pugh classification B and C)\n* Left ventricular thrombus\n* Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis\n* Known contraindication for any DOAC or VKA\n* Women who are pregnant, breastfeeding, or of childbearing potential\n* Follow-up not possible",{"count":131,"type":19},120,[133],"PHASE3","SAFE-HEART is a single-centre, randomized controlled trial comparing the safety and efficiency of Apixaban versus Warfarin in the early period (3 months) after repair or bioprosthetics of the mitral and aortic valve cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.",[26,25,136,137,138,139,140],"Valve Replacement Surgery","Aortic Valve Surgery","Mitral Valve Annuloplasty","Mitral Valve Repair","Mitral Valve Surgery",[142,143,144,145,146,147,148],"anticoagulation","bioprosthetics","atrial fibrillation","mitral valve repair","aortic valve repair","Apixaban","Warfarin","2026-02-20",{"date":151,"type":37},"2026-02-25",{"date":153,"type":19},"2026-02",{"date":155,"type":19},"2029-01",{"name":157,"class":158},"Meshalkin Research Institute of Pathology of Circulation","NETWORK",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":100},"100586608","mosaic-mitral-valve-long-term-outcomes-in-patients-under-65-100586608","NCT06917586","Mosaic Mitral Valve: Long-Term Outcomes in Patients Under 65","Long Term Patient Outcomes and Product Durability of the Mosaic Mitral Valve Bioprosthesis in Patients Under 65","MMV","Inclusion Criteria:\n\n* Received the Mosaic Mitral Valve Bioprosthetic at ProMedica Toledo Hospital\n* Under the age of 65\n\nExclusion Criteria:\n\n* Over the age of 65\n* Under the age of 18\n* Surgery performed at institutions outside of ProMedica Toledo Hospital","65 Years",{"count":169,"type":19},300,"The safety and efficacy of the Mosaic bioprosthetic heart valves for cardiac valve replacement in the aortic position has been well documented throughout the literature. However, few studies assessing structural valve deficiency, patient outcomes and overall product performance in patients under the age of 65 exists for the Mosaic mitral valve bioprosthetic. This study aims to assess valve efficacy, stability, and post operative outcomes in patients who have received the Mosaic mitral valve prothesis at ProMedica Toledo Hospital and were under the age of 65.",[26,172,173,62],"Valve Replacement","Valve Regurgitation, Mitral",[175,176,177,178],"Mitral Valve","Bioprosthetic","Mosaic","Valvulopathy","2026-02-18",{"date":149,"type":37},{"date":182,"type":37},"2025-01-01",{"date":184,"type":19},"2027-07-01",{"name":186,"class":76},"Michael Moront",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":194,"targetDuration":196,"studyType":21,"phases":4,"briefSummary":197,"conditions":198,"keywords":204,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":218},"100608082","valvular-heart-disease-in-women-registry-100608082","NCT07196930","Valvular Heart Disease in Women Registry","VHD-W","Inclusion Criteria:\n\n* Adult patients with diagnosis of any VHD according to the current ESC guidelines.\n* Admission to the VHD-W Registry collaborating center.\n\nExclusion Criteria:\n\n* Age less than 18 years old.\n* Inability to provide informed consent per local institutional and regulatory requirements.",{"count":195,"type":19},800,"1 Year","Valvular heart disease (VHD) is a major global health issue. Untreated rheumatic heart disease persists in many regions, preventable with timely care. Higher-income countries face rising calcific valve disease from aging, worsened by VHD complications, like infective endocarditis, resulting in higher morbidity\u002Fmortality. Gender disparities in VHD remains understudied, despite inequalities in risks, diagnosis, and treatment. Prevalence varies by gender, but uneven diagnostics and therapies obscure realities. This registry will examine gender disparities from hospital admission to first outpatient follow-up, recruiting both men and women to investigate and report the study objectives.",[26,199,200,201,202,203],"Gender Bias","Guideline Adherence","Guideline Implementation","Disparities","Registry",[205,206,207,208,209],"valvular heart disease","registry","cardiovascular disease","gender disparities","Guidelines adherence","2025-09-19",{"date":212,"type":37},"2025-09-29",{"date":214,"type":37},"2024-04-01",{"date":216,"type":19},"2030-12",{"name":191,"class":158},2,{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":227,"conditions":228,"keywords":236,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":100},"100513945","integration-of-telemedicine-and-home-based-cardiac-rehabilitation-feasibility-efficacy-and-adherence-100513945","NCT05972070","Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence","Inclusion Criteria:\n\n1. Over the age of 18\n2. NYHA Functional Class I, II,\n3. Recent (within 60 days) status post coronary artery revascularization for atherosclerotic coronary artery disease (coronary artery bypass grafting or percutaneous coronary revascularization with stent implantation)\n4. Candidate for traditional center-based cardiac rehabilitation\n\nExclusion Criteria:\n\n1. Under the age of 18\n2. Adults lacking capacity to consent.\n3. NYHA Functional Class III, IV\n4. Acute coronary syndrome\n5. Systolic heart failure (LV EF \\\u003C40%)\n6. Status post cardiac surgery for structural heart disease or heart transplant\n7. Percutaneous coronary angioplasty\n8. Adults lacking capacity to consent.\n9. Pregnant women",{"count":226,"type":19},500,"The aim of this study is to evaluate feasibility, efficacy, and adherence of home-based cardiac rehabilitation with the integration of telemedicine. Several components will be assessed such as quality-of-life, nutritional counseling, maximum metabolic activity (MET's), diabetic management, tobacco cessation, lipid, blood pressure, and psychosocial management. These tasks will be accomplished through concurrent conversations between patients and their therapist's utilizing telemedicine with observed exercise training.",[229,230,231,232,233,26,234,235],"Myocardial Infarction","Percutaneous Transluminal Coronary Angioplasty","Coronary Artery Bypass","Stable Angina","Heart Failure","Cardiac Rehabilitation","Stent",[237,238,239],"Cardiac rehabilitation","Home based cardiac rehabilitation","Telemedicine and Home-Based Cardiac Rehabilitation","2025-07-21",{"date":242,"type":37},"2025-07-24",{"date":244,"type":37},"2023-06-01",{"date":246,"type":19},"2025-12-31",{"name":248,"class":44},"ROM Technologies, INC",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":15,"minAge":255,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":269},"100597472","the-asia-pacific-mitral--tricuspid-valve-in-valvevalve-in-ring-registry-ap-viv-registry-100597472","NCT07058935","The Asia-Pacific Mitral & Tricuspid Valve-in-Valve\u002FValve-in-Ring Registry (AP ViV Registry)","Inclusion Criteria:\n\n1. Age ≥ 21\n2. Had at least one documented Mitral valve-in-valve\u002Fvalve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Mitral valve-in-valve\u002Fvalve-in-ring procedure. (Prospective) OR Had at least one documented Tricuspid valve-in-valve\u002Fvalve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Tricuspid valve-in-valve\u002Fvalve-in-ring procedure. (Prospective)\n\nExclusion Criteria:\n\n1. Active endocarditis\n2. Any other conditions which investigator deems unsuitable for participation.","21 Years",{"count":257,"type":19},150,"A retrospective and prospective, observational, multicenter cohort study of consecutive patients undergoing transcatheter mitral\u002Ftricuspid ViV or ViR procedure with balloon expandable valve across participating sites in Asia-Pacific.",[26],"2025-07-01",{"date":262,"type":37},"2025-07-10",{"date":264,"type":37},"2025-03-17",{"date":266,"type":19},"2035-12",{"name":268,"class":76},"National Heart Centre Singapore",8,{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":15,"minAge":276,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":54,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":100},"100545863","allogeneic-valve-transplantation-100545863","NCT06387446","Allogeneic Valve Transplantation","Inclusion Criteria\n\n* Patients requiring aortic, pulmonary, mitral or tricuspid valve replacement.\n* Pediatric patients 30 days or older and \\\u003C 18 years, and adult patients 18-50 yrs.\n\n  o Particularly patients with significant growth potential\n* Insufficient options are available for valve replacement\n\n  o Patients at risk of immunogenic bio-prosthetic valve failure\n* Discussion with patient \u002Ffamily - option for durable valve rather than traditional prosthesis\n* ABO compatible\n* Patient and family able to travel to BCH within 48 hour time frame or within our organ procurement organization\n* Patients that are able to maintain follow-up at BCH during the duration of the study\n* Patients that are able to provide medical record authorization for 5 year follow-up\n\nExclusion Criteria\n\n* Age \\\u003C 30 days\n* Irreversible multisystem organ failure; or additive effects of the multiple systems affected making transplant survival unlikely\n* Progressive systemic disease with early mortality (genetic\u002Fmetabolic, idiopathic, syndromic)\n* Morbid obesity (BMI\\>35)\n* Diabetes mellitus with evidence of end-organ damage\n* Severe chromosomal, neurologic or syndromic abnormalities\n* Immunocompromised condition (DiGeorge, SCID etc.)\n* Active infection\n* History of endocarditis\n* HIV or chronic hepatitis B or C infection\n* Malignancy within 5 years prior to transplant\n* Severe renal or liver failure\n* Inadequate social support for post-transplant management\n* Recent history of illicit drug, tobacco or alcohol abuse despite trials\u002Fassistance to stop behavior\n* Evidence of large stroke with high risk for hemorrhagic conversion\n* Heart transplant recipient\n* Patients that are unable to follow-up during the initial 6 month window\n* Patients that are unable to provide medical record authorization for 5 years","30 Days","50 Years",{"count":279,"type":19},4,[56],"Valves will be taken from hearts donated by organ donors, and implanted into patients who need a new heart valve.",[283,26,284],"Valve Heart Disease","Valve Disease, Aortic","2024-09-22",{"date":287,"type":37},"2024-09-24",{"date":289,"type":37},"2024-05-01",{"date":291,"type":19},"2027-06-01",{"name":293,"class":76},"Boston Children's Hospital",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":302,"targetDuration":110,"studyType":21,"phases":4,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":100},"100449984","the-endocarditis-aumc-data-collection-100449984","NCT05139589","The ENDOCARDITIS AUMC Data Collection","The ENDOCARDITIS AUMC Data Collection : a Matched Cohort Study on Perioperative Coagulation in Conservatively and Surgically Treated Patients With Valvular Dysfunction, With and Without Infective Endocarditis","ENDO_AUMC","Inclusion Criteria:\n\n* Patients \\> 18 years\n* Dutch or English speaking\n* All patients with infective endocarditis admitted to Amsterdam UMC in the study period\n* All patients with infective endocarditis scheduled for cardiac valve surgery compared to a matched cohort of patients scheduled for similar surgery due to non-infectious indication in Amsterdam UMC in the same period\n\nExclusion Criteria:\n\n* Previous history of coagulation disorders",{"count":303,"type":19},3000,"The investigators will compare patients with and without infective ndocarditis undergoing valve surgery and evaluate factors that may help optimise perioperative care of these high-risk patients.",[306,307,26],"Endocarditis","Coagulation Disorder","2023-07-24",{"date":310,"type":37},"2023-07-25",{"date":312,"type":19},"2023-08-06",{"date":314,"type":19},"2030-12-31",{"name":316,"class":76},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"]